

1 **Identifying Ashkenazi Jewish *BRCA1/2* founder variants in individuals who do not self-**  
2 **report Jewish ancestry**

3

4 Ruth I. Tennen<sup>1</sup>, Sarah B. Laskey<sup>1</sup>, Bertram L. Koelsch<sup>1</sup>, Matthew H. McIntyre<sup>1</sup>, The 23andMe  
5 Health Team<sup>1</sup>, Joyce Y. Tung<sup>1\*</sup>

6

7 <sup>1</sup>23andMe, Inc., 899 W Evelyn Ave, Mountain View, CA, 94041 USA

8 \*Correspondence should be addressed to J.Y.T. ([joyce@23andme.com](mailto:joyce@23andme.com))

## 9 ABSTRACT

10 Current guidelines recommend *BRCA1* and *BRCA2* genetic testing for individuals with a  
11 personal or family history of certain cancers. Three *BRCA1/2* founder variants — 185delAG  
12 (c.68\_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) — are common in the  
13 Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research  
14 participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish  
15 founder variants, evaluating two characteristics that are typically used to recommend individuals  
16 for *BRCA* testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate,  
17 or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information,  
18 21% did not self-report any Jewish ancestry; of these individuals, more than half (62%) do have  
19 detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided  
20 both ancestry and family history information, 44% did not have a first-degree family history of a  
21 *BRCA*-related cancer and, in the absence of a personal history of cancer, would therefore be  
22 unlikely to qualify for clinical genetic testing. These findings provide support for the growing call  
23 for broader access to *BRCA* genetic testing.

24

25 **Keywords:** BRCA1, BRCA2, genetic testing, Ashkenazi Jewish, family history

26

## 27 **MAIN TEXT**

### 28 **BACKGROUND**

29 Pathogenic variants in the *BRCA1* and *BRCA2* genes are linked to an increased risk for female  
30 breast and ovarian cancer (including early-onset breast cancer), male breast cancer, prostate  
31 cancer, pancreatic cancer, and certain other cancers [1]. These variants are highly penetrant:  
32 Women with a variant have a 45-85% chance of developing breast cancer and up to a 46%  
33 chance of developing ovarian cancer by age 70 [2]. However, increased surveillance and  
34 prophylactic surgery (mastectomy and salpingo-oophorectomy) can greatly reduce the risk of  
35 breast and ovarian cancer in women carrying a *BRCA1* or *BRCA2* mutation [3].

36  
37 The prevalence of pathogenic *BRCA1* and *BRCA2* variants is estimated to be between 1 in 300  
38 and 1 in 800 in the general population [1,2]. Among individuals of Ashkenazi Jewish descent,  
39 three *BRCA1/2* founder variants — 185delAG (c.68\_69delAG), 5382insC (c.5266dupC), and  
40 6174delT (c.5946delT) — are present at a frequency of ~1 in 40 [1].

41  
42 Current U.S. guidelines limit *BRCA1/2* genetic testing to individuals with a personal or family  
43 history of a relevant cancer, including early-onset breast cancer, multiple primary breast  
44 cancers, ovarian cancer, and certain other cancers [1,2,4]. In addition, Ashkenazi Jewish  
45 ancestry is sometimes used to recommend screening for individuals with a personal or family  
46 history of a single breast cancer at any age [1]. However, recent studies have found that about  
47 50% of *BRCA* carriers have little or no family history of a relevant cancer [5-8]. These  
48 individuals would likely not qualify for clinical genetic testing unless they developed cancer  
49 themselves, representing a missed opportunity for cancer prevention. Because *BRCA* variants  
50 predispose to very high breast and ovarian cancer risks even among carriers without a family

51 history [5,9], these findings have spurred calls for broader access to *BRCA* genetic testing,  
52 among Ashkenazi Jews and in the general population [5-7,10,11].

53  
54 The 23andMe database provides an ethnically diverse, generally unselected group of  
55 genotyped individuals. We sought to characterize a cohort of individuals who carry one or more  
56 of the three Ashkenazi Jewish founder variants as related to two characteristics that are typically  
57 used to recommend individuals for *BRCA* testing: self-reported Jewish ancestry and family  
58 history of breast, ovarian, prostate, or pancreatic cancer. We focused on these two  
59 characteristics because they can enable individuals to learn their *BRCA* status before  
60 developing cancer, thus providing opportunities for cancer prevention and/or early detection.

61

## 62 **METHODS**

63 Consented participants were drawn from the customer base of 23andMe. Data on Jewish  
64 ancestry and family cancer history were collected by self-report via online surveys. See  
65 Declarations for informed consent and protocol details; see Supplementary Information for  
66 survey questions. Analyses were run on phenotypic data collected before October 10, 2017.

67

68 DNA extraction and genotyping were performed on saliva samples by CLIA-certified and CAP-  
69 accredited clinical laboratories of Laboratory Corporation of America. Samples were genotyped  
70 on one of four custom Illumina genotyping arrays: the HumanHap550+ Bead chip (two  
71 versions), the OmniExpress+ Bead chip, or a fully custom array; see [12] for additional details.  
72 Proportions of Ashkenazi Jewish genetic ancestry were estimated via an analysis of local  
73 genetic ancestry as described in [13]. To account for imprecision in genetic ancestry estimates,  
74 we characterized estimates of Ashkenazi Jewish genetic ancestry <1% as "not detectable."

75

76

77 **RESULTS**

78 We identified 2,853 individuals who carry one or more of the three Ashkenazi Jewish *BRCA1/2*  
79 founder variants (Table 1).

80  
81 **Table 1.** Demographics of individuals carrying one or more of the three Ashkenazi Jewish  
82 *BRCA* founder variants

Age (years)	Men	Women
Overall	1539	1314
18-30	205 (13.3%)	186 (14.2%)
31-50	517 (33.6%)	461 (35.1%)
51-70	550 (35.7%)	510 (38.8%)
71+	267 (17.3%)	157 (11.9%)

83  
84 We first characterized the ethnic backgrounds of the carriers. The three variants in this study  
85 are most common in people of Ashkenazi Jewish descent. However, among carriers who  
86 provided self-reported ancestry information, 21% did not report Jewish ancestry (Table 2).

87  
88 **Table 2.** Self-reported Jewish ancestry in the cohort of *BRCA* carriers

Total <i>BRCA</i> carriers	2853
Provided self-reported ancestry	1967 (68.9%, of 2853)
- <i>BRCA1</i> 185delAG	748 (38.0%, of 1967)
- <i>BRCA1</i> 5382insC	415 (21.1%, of 1967)
- <i>BRCA2</i> 6174delT	811 (41.2%, of 1967)
- Self-reported Jewish ancestry	1552 (78.9%, of 1967)
- Did not self-report Jewish ancestry	415 (21.1%, of 1967)

89 The total number of *BRCA* variants detected exceeds the total number of individuals in the  
90 cohort because a small number of participants carry both a *BRCA1* and a *BRCA2* variant.

91  
 92 One possible explanation for the large fraction of carriers who did not report Jewish ancestry is  
 93 that they were unaware of their Ashkenazi Jewish ancestry. To test this hypothesis, we explored  
 94 the relationship between self-reported ancestry and genetic ancestry. As expected, individuals  
 95 with a greater proportion of estimated Ashkenazi Jewish genetic ancestry were more likely to  
 96 report Jewish ancestry (Table 3 and Figure 1); fewer than half of individuals with less than 20%  
 97 Ashkenazi Jewish genetic ancestry (roughly equivalent to one grandparent or great-grandparent  
 98 who was Ashkenazi Jewish) reported Jewish ancestry. Furthermore, most (62%, 258 of 415) of  
 99 the *BRCA* carriers who reported no Jewish ancestry did have at least 1% Ashkenazi Jewish  
 100 genetic ancestry. However, a lack of knowledge of Ashkenazi Jewish ancestry could not fully  
 101 account for the 21% of carriers who did not report Jewish ancestry, as 8.4% (166 of 1,967) of  
 102 individuals carrying an Ashkenazi Jewish founder variant had no detectable Ashkenazi Jewish  
 103 genetic ancestry. This is consistent with the finding that at least two of these variants are also  
 104 found in people of other ethnicities [14]. Nine individuals reported Jewish ancestry but had no  
 105 detectable Ashkenazi Jewish genetic ancestry.

106  
 107 **Table 3.** Self-reported Jewish ancestry vs. estimated Ashkenazi Jewish genetic ancestry in  
 108 1,967 *BRCA* carriers


Likely last fully Ashkenazi Jewish ancestor	% calculated Ashkenazi Jewish genetic ancestry	Self-reported Jewish ancestry	Did not self-report Jewish ancestry
Self	85-100%	972	10
1 parent or 2-3 grandparents	40-84%	419	41
1 grandparent	20-39%	88	29
1 grandparent or great-grandparent	10-19%	33	34
1 great-grandparent	5-9%	7	17

More distant than great-grandparent	1-4%	24	127
No detectable Ashkenazi Jewish ancestry	0%	9	157

109

110

111 **Figure 1.** Self-reported Jewish ancestry vs. estimated Ashkenazi Jewish genetic ancestry in  
 112 1,967 *BRCA* carriers



113

114 The primary criterion for *BRCA* genetic testing is a personal or family history of breast, ovarian,  
 115 or certain other cancers (including prostate and pancreatic cancer). We therefore assessed  
 116 whether the carriers in our cohort had any family history of cancer. 393 carriers provided family  
 117 history information.

118

119 Among participants who reported Jewish ancestry, 41% reported no first-degree family history  
 120 of a *BRCA*-related cancer (Table 4). Similarly, 54% of participants who did not report Jewish  
 121 ancestry reported no first-degree family history of cancer. Although our family history data

122 differs substantially from guidelines used to determine genetic testing eligibility (which often  
123 include age of diagnosis and more than one cancer of certain types), this number is consistent  
124 with previous reports that about 50% of *BRCA* carriers would not be eligible for genetic testing  
125 based on family history alone [5-8].

126

127 **Table 4.** Self-reported family history of cancer in 393 *BRCA* carriers

		Total number who provided family history information	Reported a family history of breast or ovarian cancer	Reported a family history of prostate or pancreatic cancer	Reported no family history of breast, ovarian, prostate, or pancreatic cancer
First-degree family history	Self-reported Jewish ancestry	310	139 (45%)	71 (23%)	127 (41%)
	Did not self-report Jewish ancestry	83	33 (40%)	9 (11%)	45 (54%)
	Total	393	172 (44%)	80 (20%)	172 (44%)

128 Percentages in each row may not sum to 100%, because some participants reported a family  
129 history of more than one type of cancer.

130

131

## 132 DISCUSSION

133 In this study, we describe a largely unselected cohort of ~2,800 individuals who carry one or  
134 more of the three Ashkenazi Jewish *BRCA1/2* founder variants. In characterizing the ancestry  
135 and family cancer histories of these individuals, we made two key observations.

136

137 First, we found that a sizeable proportion (21%) of the carriers in our cohort do not self-report  
138 Jewish ancestry. Of these individuals, more than half (62%) do have detectable Ashkenazi  
139 Jewish genetic ancestry, although frequently in very low percentages (Table 3 and Figure 1).

140 Interestingly, 8% of all carriers have no detectable Ashkenazi Jewish genetic ancestry,



141 consistent with reports that *BRCA1* 185delAG and 5382insC are found in women of other  
142 ethnicities who are referred for clinical genetic testing [14].

143  
144 Second, we observed that nearly half of individuals carrying an Ashkenazi Jewish *BRCA* variant  
145 have no first-degree family history of a *BRCA*-related cancer and, in the absence of a personal  
146 cancer history, would therefore be unlikely to qualify for clinical genetic testing. This percentage  
147 is consistent with published reports that about 50% of *BRCA* carriers lack a strong family history  
148 of cancer [5-8].

149  
150 Limitations of this study include a potential ascertainment bias related to family cancer history,  
151 as individuals with such histories may be more likely to answer questions about family cancer  
152 history. In addition, due to the limited depth of our family history survey, we defined family  
153 history as having a first-degree relative with breast, ovarian, prostate, or pancreatic cancer;  
154 clinical testing criteria are typically stricter, requiring an early age of diagnosis and/or more than  
155 one affected family member. Together, these two points suggest that our estimate of the fraction  
156 of individuals who would be ineligible for testing based on family history alone under existing  
157 screening guidelines is likely lower than the true fraction. Finally, because not all individuals in  
158 this study provided ancestry and family history information, the number of individuals included in  
159 some analyses is fairly small.

160  
161 Our data suggest that a sizeable fraction of individuals with detectable Ashkenazi Jewish  
162 genetic ancestry are unaware of that ancestry. This phenomenon is likely not unique to  
163 Ashkenazi Jewish ancestry. In addition to *BRCA*-related cancers, many other conditions are  
164 more common in specific ancestral groups, including Tay-Sachs disease, Canavan disease, and  
165 Gaucher disease type 1 in Ashkenazi Jews; sickle cell anemia in individuals with African  
166 ancestry; and beta-thalassemia in individuals with Mediterranean and certain other ancestries.

167 For individuals who are unaware of their genetic ancestry, perceived risk for diseases could thus  
168 differ substantially from actual risk, which could lead to missed opportunities for genetic  
169 screening, prevention, and early intervention.

170  
171 In recent years, several groups have called for broader access to *BRCA* genetic testing among  
172 Ashkenazi Jews and among women in the general population [5-7,10,11]. Among Ashkenazi  
173 Jews, where testing for the three founder variants can identify most *BRCA* carriers, population-  
174 wide screening is cost-effective or even cost-saving [15]; in other ethnicities, more  
175 comprehensive genetic testing would be required to identify most individuals carrying a *BRCA*  
176 variant, but depending on the source of testing, this may also be cost-effective [16]. Our data  
177 provide support for this growing call for expanded *BRCA* testing. Such testing would enable  
178 women and men with a *BRCA* variant to learn their status, take steps to reduce their cancer  
179 risk, and encourage cascade testing of close family members.

180

## 181 **DECLARATIONS**

### 182 **Ethics approval and consent to participate**

183 All participants provided informed consent and answered surveys online according to a research  
184 protocol approved by Ethical and Independent Review Services, an external AAHRPP-  
185 accredited institutional review board.

186

### 187 **Availability of data**

188 All data generated or analyzed during this study are included in the manuscript.

189

### 190 **Competing interests**

191 R.I.T., S.B.L., B.L.K, M.H.M., J.Y.T., and members of The 23andMe Health Team are current or  
192 former employees of and have stock, stock options, or both, in 23andMe, Inc.

193

## 194 **Funding**

195 No external funding was received for this study.

196

## 197 **Authors' contributions**

198 Study concept and design: J.Y.T. and R.I.T. Acquisition and analysis of data: J.Y.T., S.B.L.,  
199 B.L.K, and M.H.M. Interpretation of data: R.I.T., S.B.L., B.L.K, M.H.M., and J.Y.T. Drafting of the  
200 manuscript: R.I.T. Critical revision of the manuscript for important intellectual content: R.I.T.,  
201 S.B.L., B.L.K, M.H.M., and J.Y.T. Support and infrastructure to enable the research presented  
202 here: The 23andMe Health Team.

203

## 204 **Acknowledgements**

205 We thank the research participants and employees of 23andMe for making this work possible.  
206 We also thank Uta Francke, Jennifer C. McCreight, and Elizabeth S. Noblin for critical review of  
207 the manuscript; David A. Hinds for scientific input; and Catherine Wilson for supporting the  
208 ancestry and cancer family history surveys.

209

210 The 23andMe Health Team: Robert K. Bell, Katarzyna Bryc, Alison L. Chubb, Stacey B.  
211 Detweiler, Anne E. Greb, Esther Kim, Michaela Johnson, Joanna L. Mountain, Jamaica R.  
212 Perry, Jeffrey D. Pollard, Shirley Wu.

213

214

## 215 **REFERENCES**

216 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-  
217 Risk Assessment: Breast and Ovarian. Version 3.2019. Available at:

- 218 [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf). Accessed 28  
219 Mar 2019.
- 220 2. Committee on Practice Bulletins—Gynecology, Committee on Genetics, Society of  
221 Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer  
222 Syndrome. *Obstet Gynecol*. 2017;130(3):e110-e126.
- 223 3. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated  
224 with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl*  
225 *Cancer Inst*. 2009;101(2):80-7.
- 226 4. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and  
227 genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force  
228 recommendation statement. *Ann Intern Med*. 2014;160(4):271-81.
- 229 5. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M,  
230 Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-  
231 Lahad E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and  
232 BRCA2. *Proc Natl Acad Sci U S A*. 2014;111(39):14205-10.
- 233 6. Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L,  
234 Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C,  
235 Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I. Population testing for cancer  
236 predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized  
237 controlled trial. *J Natl Cancer Inst*. 2015;107(1):379.
- 238 7. Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA. A comparison of  
239 the detection of BRCA mutation carriers through the provision of Jewish population-based  
240 genetic testing compared with clinic-based genetic testing. *Br J Cancer*. 2013;109(3):777-9.
- 241 8. Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha  
242 H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R,  
243 Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton

- 244 JD4 Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA,  
245 Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE,  
246 Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS,  
247 Ledbetter DH, Murray MF. Exome Sequencing-Based Screening for BRCA1/2 Expected  
248 Pathogenic Variants Among Adult Biobank Participants. *JAMA Netw Open*.  
249 2018;1(5):e182140.
- 250 9. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S,  
251 van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF,  
252 Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale  
253 D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis  
254 S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van  
255 der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB,  
256 Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J,  
257 Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E,  
258 Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer  
259 for BRCA1 and BRCA2 Mutation Carriers. *JAMA*. 2017;317(23):2402-2416.
- 260 10. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2:  
261 2014 Lasker Award. *JAMA*. 2014;312(11):1091-2.
- 262 11. Akbari MR, Gojska N, Narod SA. Coming of age in Canada: a study of population-based  
263 genetic testing for breast and ovarian cancer. *Curr Oncol*. 2017;24(5):282-283.
- 264 12. Sanchez-Roige S, Fontanillas P, Elson SL, 23andMe Research Team, Pandit A, Schmidt  
265 EM, Foerster JR, Abecasis GR, Gray JC, de Wit H, Davis LK, MacKillop J, Palmer AA.  
266 Genome-wide association study of delay discounting in 23,217 adult research participants of  
267 European ancestry. *Nat Neurosci*. 2018;21(1):16-18.
- 268 13. Durand, E.Y., Do, C.B., Mountain, J.L., Macpherson, J.M. Ancestry Composition: A Novel,  
269 Efficient Pipeline for Ancestry Deconvolution | bioRxiv. Available at:

- 270 <https://www.biorxiv.org/content/10.1101/010512v1>. Accessed 28 Mar 2019.
- 271 14. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE,  
272 Scholl TA, Noll WW. BRCA1 and BRCA2 mutations in women of different ethnicities  
273 undergoing testing for hereditary breast-ovarian cancer. *Cancer*. 2009;115(10):2222-33.
- 274 15. Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J,  
275 Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y,  
276 Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I. Cost-  
277 effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women  
278 compared with family history-based testing. *J Natl Cancer Inst*. 2015;107(1):380.
- 279 16. Long EF, Ganz PA. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based  
280 Decision Making. *JAMA Oncol*. 2015;1(9):1217-8.

## 1 SUPPLEMENTARY INFORMATION

2

### 3 ***Jewish ancestry***

4 Do you have any Jewish ancestry?

5  Yes

6  No

7  I'm not sure

8

9 Participants who answered "Yes" were counted as self-reporting Jewish ancestry; participants  
10 who answered "No" were counted as not self-reporting Jewish ancestry; and participants who  
11 answered "I'm not sure" were not counted.

12

### 13 ***Family history***

14 Participants provided information about family history of cancer in one of three surveys, which  
15 included slightly different versions of the family history questions. Functionally, there were two  
16 versions of the family history questions (described below). Version 1 was in one survey while  
17 Version 2 was in two surveys. Relevant questions from each survey are excerpted below.

18

#### 19 **Version 1**

20 Is your family's history of cancer completely unknown to you for some reason, such as being  
21 adopted?

22  Yes

23  No

24

25 *Please indicate below whether your biological parents or grandparents have ever had cancer.*  
26 *[Grandparental history was not used.]*

27 Your mother

28  Yes

29  No

30  I'm not sure

31

32 Your father

33  Yes

34  No

35  I'm not sure

36

37 *Have any of your other biological relatives, listed below, had cancer?*

38 Your child(ren)

39  Yes

40  No

41  Not applicable

42  I'm not sure

43

44 Your sister(s)

- 45  Yes  
46  No  
47  Not applicable  
48  I'm not sure

49  
50 Your brother(s)

- 51  Yes  
52  No  
53  Not applicable  
54  I'm not sure

55  
56 {Where <female relative> could be “mother” or “sister”}

57 What type(s) of cancer was your <female relative> diagnosed with? Please check all that apply.

- 58  Adrenal gland cancer  
59  Anal cancer  
60  Bladder cancer  
61  Biliary tract cancer  
62  Brain cancer  
63  Breast cancer  
64  Cervical cancer  
65  Colon/colorectal cancer  
66  Endometrial or uterine cancer  
67  Esophageal cancer  
68  Gallbladder cancer  
69  Hodgkin's lymphoma  
70  Kidney/renal cancer  
71  Leukemia, any type  
72  Liver/bile ducts (hepatobiliary) cancer  
73  Lung cancer  
74  Melanoma  
75  Mouth (oral) cancer  
76  Non-Hodgkin's lymphoma  
77  Pancreatic cancer  
78  Ovarian cancer  
79  Salivary gland cancer  
80  Sarcoma, any type  
81  Skin cancer (not melanoma)  
82  Small intestine/duodenal cancer  
83  Stomach/gastric cancer  
84  Throat cancer  
85  Thyroid cancer  
86  Ureter/renal pelvis cancer  
87  Vaginal cancer  
88  Vulval cancer



89  Another type of cancer: \_\_\_\_\_

90  I'm not sure

91

92 {Where <male relative> could be “father” or “brother”}

93 What type(s) of cancer was your <male relative> diagnosed with? Please check all that apply.

94  Adrenal gland cancer

95  Anal cancer

96  Bladder cancer

97  Biliary tract cancer

98  Brain cancer

99  Breast cancer

100  Colon/colorectal cancer

101  Esophageal cancer

102  Gallbladder cancer

103  Hodgkin's lymphoma

104  Kidney/renal cancer

105  Leukemia, any type

106  Liver/bile ducts (hepatobiliary) cancer

107  Lung cancer

108  Melanoma

109  Mouth (oral) cancer

110  Non-Hodgkin's lymphoma

111  Pancreatic cancer

112  Prostate cancer

113  Salivary gland cancer

114  Sarcoma, any type

115  Skin cancer (not melanoma)

116  Small intestine/duodenal cancer

117  Stomach/gastric cancer

118  Testicular cancer

119  Throat cancer

120  Thyroid cancer

121  Ureter/renal pelvis cancer

122  Another type of cancer: \_\_\_\_\_

123  I'm not sure

124

125 What type(s) of cancer was your child(ren) diagnosed with? Please check all that apply.

126  Adrenal gland cancer

127  Anal cancer

128  Bladder cancer

129  Biliary tract cancer

130  Brain cancer

131  Breast cancer

132  Cervical cancer

- 133  Colon/colorectal cancer
- 134  Endometrial or uterine cancer
- 135  Esophageal cancer
- 136  Gallbladder cancer
- 137  Hodgkin's lymphoma
- 138  Kidney/renal cancer
- 139  Leukemia, any type
- 140  Liver/bile ducts (hepatobiliary) cancer
- 141  Lung cancer
- 142  Melanoma
- 143  Mouth (oral) cancer
- 144  Non-Hodgkin's lymphoma
- 145  Pancreatic cancer
- 146  Prostate cancer
- 147  Ovarian cancer
- 148  Salivary gland cancer
- 149  Sarcoma, any type
- 150  Skin cancer (not melanoma)
- 151  Small intestine/duodenal cancer
- 152  Stomach/gastric cancer
- 153  Testicular cancer
- 154  Throat cancer
- 155  Thyroid cancer
- 156  Ureter/renal pelvis cancer
- 157  Vaginal cancer
- 158  Vulval cancer
- 159  Another type of cancer: \_\_\_\_\_
- 160  I'm not sure

161

162 Have you ever been diagnosed with any of these hereditary cancer syndromes?

- 163  Cowden syndrome
- 164  Familial adenomatous polyposis
- 165  Hereditary breast and ovarian cancer syndrome (HBOC)
- 166  Li-Fraumeni syndrome
- 167  Lynch syndrome (hereditary non-polyposis colorectal cancer syndrome)
- 168  Multiple endocrine neoplasias
- 169  Von Hippel-Lindau Disease
- 170  I'm not sure
- 171  None of the above

172

173 **Version 2**

174 *Please indicate below whether your biological parents, siblings, or children have ever had*  
175 *cancer.*

176 Your mother

- 177         Yes  
178         No  
179         I'm not sure  
180  
181    Your father  
182         Yes  
183         No  
184         I'm not sure  
185  
186    Your sibling(s)  
187         Yes  
188         No  
189         I'm not sure  
190  
191    Your child(ren)  
192         Yes  
193         No  
194         I'm not sure  
195  
196    How many biological siblings do you have? \_\_\_\_\_  
197  
198    How many biological children do you have? \_\_\_\_\_  
199  
200    What type(s) of cancer was your biological mother diagnosed with or treated for? Please select  
201    all that apply.  
202         Bladder cancer  
203         Brain cancer  
204         Breast cancer  
205         Colon/colorectal cancer  
206         Endometrial or uterine cancer  
207         Hodgkin's lymphoma  
208         Kidney/renal cancer  
209         Leukemia, any type  
210         Liver cancer  
211         Lung cancer  
212         Myeloma  
213         Non-Hodgkin's lymphoma  
214         Ovarian cancer  
215         Pancreatic cancer  
216         Skin cancer  
217         Stomach cancer  
218         Thyroid cancer  
219         Another type of cancer  
220         I'm not sure

- 221  
222 What type(s) of cancer was your biological father diagnosed with or treated for? Please select  
223 all that apply.
- 224  Bladder cancer
  - 225  Brain cancer
  - 226  Colon/colorectal cancer
  - 227  Esophageal cancer
  - 228  Hodgkin's lymphoma
  - 229  Kidney/renal cancer
  - 230  Leukemia, any type
  - 231  Liver cancer
  - 232  Lung cancer
  - 233  Mouth (oral) cancer
  - 234  Myeloma
  - 235  Non-Hodgkin's lymphoma
  - 236  Pancreatic cancer
  - 237  Prostate cancer
  - 238  Skin cancer
  - 239  Stomach cancer
  - 240  Thyroid cancer
  - 241  Another type of cancer
  - 242  I'm not sure
- 243  
244 How many of your biological siblings have ever had cancer? \_\_\_\_\_  
245
- 246 What type(s) of cancer was your biological sibling(s) diagnosed with or treated for? Please  
247 select all that apply.
- 248  Bladder cancer
  - 249  Brain cancer
  - 250  Breast cancer
  - 251  Colon/colorectal cancer
  - 252  Endometrial or uterine cancer
  - 253  Esophageal cancer
  - 254  Hodgkin's lymphoma
  - 255  Kidney/renal cancer
  - 256  Leukemia, any type
  - 257  Liver cancer
  - 258  Lung cancer
  - 259  Mouth (oral) cancer
  - 260  Myeloma
  - 261  Non-Hodgkin's lymphoma
  - 262  Ovarian cancer
  - 263  Pancreatic cancer
  - 264  Prostate cancer

265  Stomach cancer

266  Skin cancer

267  Thyroid cancer

268  Another type of cancer

269  I'm not sure

270

271 How many of your biological children have ever had cancer? \_\_\_\_\_

272

273 What type(s) of cancer was your biological child(ren) diagnosed with or treated for? Please

274 select all that apply.

275  Bladder cancer

276  Brain cancer

277  Breast cancer

278  Colon/colorectal cancer

279  Endometrial or uterine cancer

280  Esophageal cancer

281  Hodgkin's lymphoma

282  Kidney/renal cancer

283  Leukemia, any type

284  Liver cancer

285  Lung cancer

286  Mouth (oral) cancer

287  Myeloma

288  Non-Hodgkin's lymphoma

289  Ovarian cancer

290  Pancreatic cancer

291  Prostate cancer

292  Stomach cancer

293  Skin cancer

294  Thyroid cancer

295  Another type of cancer

296  I'm not sure

297

298 Have any of your biological parents, siblings, or children ever been diagnosed with any of these

299 hereditary cancer syndromes?

300  Cowden syndrome

301  Familial adenomatous polyposis

302  Hereditary breast and ovarian cancer syndrome (HBOC)

303  Li-Fraumeni syndrome

304  Lynch syndrome (hereditary non-polyposis colorectal cancer syndrome)

305  Multiple endocrine neoplasias

306  Von Hippel-Lindau Disease

307  I'm not sure

308  None of the above